Diabetes Manufacturers Brace Under Shifting Market Dynamics
Growing competition in the space has necessitated smart plays in clinical development, commercial strategy and pricing as firms like Sanofi, Novo Nordisk, Lilly and AstraZeneca fight to hold onto their share of the massive market.
You may also be interested in...
ELIXA trial results show neither increased nor decreased risk of major adverse cardiovascular events; Sanofi's diabetes drug, still unapproved in the U.S., becomes the only GLP-1 receptor agonist with CV outcomes data.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.